Hovilpri Patent Expiration

Hovilpri is a drug owned by Aicuris Anti-infective Cures Ag. It is protected by 5 US drug patents filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 26, 2032. Details of Hovilpri's patents and their expiration are given in the table below.

Filter patents by

NEW
Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire.
US9340535 N-[5-(Aminosulfony1)-4-Methyl-1,3-Thiazol-2-Yl]-N-Methyl-2-[4-(2-Pyridinyl)Phenyl]Acetamide Mesylate Monohydrate
Sep, 2032

(5 years from now)

Active
USRE49697 NA
Sep, 2032

(5 years from now)

Active
US9889124 Crystalline N-[5-(Aminosulfonyl)-4-Methyl-1,3-Thiazol-2-Yl]-N-Methyl-2-[4-(2-Pyridinyl)Phenyl]Acetamide Mono Mesylate Monohydrate Having A Specific Particle Size Distribution Range And A Specific Surface Area Range For Use In Pharmaceutical Formulations
Sep, 2032

(5 years from now)

Active
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9119786 Crystalline N-[5-(Aminosulfonyl)-4-Methyl-1,3-Thiazol-2-Yl]-N-Methyl-2-[4-(2-Pyridinyl)Phenyl]Acetamide Mono Mesylate Monohydrate Having A Specific Particle Size Distribution Range And A Specific Surface Area Range For Use In Pharmaceutical Formulations
Sep, 2032

(5 years from now)

Active
US8784887 Pharmaceutical Preparation Of N-[5-(Aminosulfonyl)-4-Methyl-1,3-Thiazol-2-Yl]-N-Methyl-2-[4-(2-Pyridinyl)Phenyl]Acetamide
Jul, 2029

(2 years from now)

Active

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Hovilpri is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Hovilpri's family patents as well as insights into ongoing legal events on those patents.

Hovilpri's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Hovilpri's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 26, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Hovilpri Generics:

There are no approved generic versions for Hovilpri as of now.





About Hovilpri

Hovilpri is a drug owned by Aicuris Anti-Infective Cures Ag. Hovilpri uses Pritelivir Mesylate as an active ingredient. Hovilpri was launched by Aicuris Anti Infect in 2026.

Approval Date:

Hovilpri was approved by FDA for market use on 09 October, 2026.

Active Ingredient:

Hovilpri uses Pritelivir Mesylate as the active ingredient. Check out other Drugs and Companies using Pritelivir Mesylate ingredient

Dosage:

Hovilpri is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 100MG BASE TABLET Prescription ORAL